Transurethral evaporation treats benign prostatic hyperplasia (BPH):
This article was originally published in Clinica
Transurethral evaporation of the prostate can cut irratative voiding complications to 22.6% say researchers from the University of Florida in Gainesville and the University of New Mexico in Albuquerque. The researchers used the technique to treat effectively benign prostatic hyperplasia (BPH) in a 168-patient study at two US sites. They found complications associated with the treatment were minimal after 12-month follow up. Patients also demonstrated a significant improvement in mean peak flow rate from 8.2 to 18.2 cm3 per second reports the Journal of Urology (Vol 157, p 1309-1312).
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.